CDK7-IN-1 tabolite N-Desmethyl Imatinib MZ-1 treatment leads to a

MZ-1 treatment leads to a reduction of the metastatic potential of these A2780 i

while potently decreases after 3 and 14 days of repeated administration in male Wistar rats weighing 180-200 g

QD) for 8 days

01 μM Hoechst 34580 at 37 °C for 70 h

Mg/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25

CDK7-IN-1 tabolite N-Desmethyl Imatinib MZ-1 treatment leads to aCDK7 IN 1, an analog of YKL 5 124, is a cyclin dependent kinase 7 (cdk7) inhibitor, with an IC50 of less than 100 nM, extracted from patent WO 2016105528 A2, Compound 215. Product information CAS Number: 1957203 02 9 Molecular Weight: 566. 05 Formula: C31H28ClN7O2 Chemical Name: (Z) N (3 {[5 chloro 4 (1H indol 3 yl)pyrimidin 2 yl]amino}phenyl) 3 [(Z) [(2E) 4 (dimethylamino) 1 hydroxybut 2 en 1 ylidene]amino]benzene 1 carboximidic acid Smiles: CN(C)C